ReviewBritish journal of clinical pharmacology2011
New anticoagulants: how to deal with treatment failure and bleeding complications.
Review in British journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Possible Factor Xa Resistance in a Patient Who Failed Apixaban and Rivaroxaban.Clinical case reports · 2024Article
- Decoding Sepsis-Induced Disseminated Intravascular Coagulation: A Comprehensive Review of Existing and Emerging Therapies.Journal of clinical medicine · 2023Review
- 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome.Acta Cardiologica Sinica · 2023Article
- Nephrotic syndrome leading to recurrent pulmonary embolism: A report of two cases.Acta bio-medica : Atenei Parmensis · 2022Article
- Anticoagulation-refractory strokes and selective infarction pattern: What's the link?Clinical case reports · 2021Article
- Management of venous thromboembolism in patients experiencing direct oral anticoagulant treatment failure: a single-center review of practice and outcomes.Journal of thrombosis and thrombolysis · 2020Article
- Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach.Cureus · 2017Article
- Should all septic patients be given systemic anticoagulation? No.Intensive care medicine · 2017Article
- Facile chemoenzymatic synthesis of biotinylated heparosan hexasaccharide.Organic & biomolecular chemistry · 2015Article
- Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.Vascular health and risk management · 2015Review
- Reversal of oral anticoagulation.Pharmacotherapy · 2013Review
- Pregnancy-specific glycoproteins bind integrin αIIbβ3 and inhibit the platelet-fibrinogen interaction.PloS one · 2013Article
- [New anticoagulants. Characteristics, monitoring and management of bleeding].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2011Review
- What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®)).Asian journal of neurosurgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional anticoagulants have proven efficacy in the management of thromboembolism. Their adverse effects and a narrow therapeutic window, necessitating regular need for monitoring, however, have long been an incentive for the development of safer anticoagulants without compromising efficacy. Over the last decade or so several new parenteral and oral anticoagulants have been launched with efficacy comparable with conventional agents. From fondaparinux to its long acting derivative idraparinux, and the factor Xa inhibitor rivaroxaban to the direct thrombin inhibitor dabigatran, the advent of new anticoagulants is radically changing anticoagulation. For conventional anticoagulants, despite their shortcomings, effective methods of reversing their anticoagulant effects exist. Moreover, strategies to deal with the occurrence of fresh thrombotic events in the face of therapeutic anticoagulation with the conventional agents have also been addressed. Nevertheless, for the new anticoagulants, the optimal management of these complications remains unknown. This review explores these issues in the light of current evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.